Completed Phase 1 clinical trial establishes gavo-cel monotherapy as the first anti-mesothelin cell therapy to demonstrate tolerability and clinical benefit
- Second RECIST partial response in ovarian cancer supports broad potential of gavo-cel- Consistent tumor regression in 28 of 30 (93%) evaluable patients with disease control rate of 77%
- Progression-free survival of 5.6 months and overall survival of 11.2 months suggest durability of benefit in mesothelioma
- Phase 2 portion of trial underway implementing multiple approaches to further improve clinical outcomes
- TCR2 to host a conference call on Wednesday, September 28, 2022 at 8:00a.m. ET
TCR2 Therapeutics will host a conference call and webcast on Wednesday, September 28, 2022 at 8:00am E.T. In order to participate in the conference call, please register at https://bit.ly/3BTJ9Z7. Participants can register via this link up to ten minutes prior to start time. The webcast and presentation will be made available on the TCR2 Therapeutics website in the Investors section under Events at investors.tcr2.com/events. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.